Astex Pharmaceuticals, Inc.
Astex Pharmaceuticals to Present at EORTC-NCI-AACR
Astex Pharmaceuticals, Inc. 31.10.2012 11:00 --------------------------------------------------------------------------- DUBLIN, Calif., 2012-10-31 11:00 CET (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced the acceptance of three abstracts for presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Poster presentations will occur Nov 7 - 9 in Dublin, Ireland. XIAP Abstract #85, Poster Board #052 Poster Presentation: Wednesday, Nov 7, 2012 12:00 - 2:15 pm GMT Characterization of a potent XIAP and cIAP1 dual antagonist in models of melanoma and leukemia AT13387 Abstract #293, Poster Board #043 Poster Presentation: Thursday, Nov 8, 2012 12:00 - 2:15 pm GMT Activity of the HSP90 inhibitor, AT13387, in ALK-driven tumor models SGI-110 Abstract #465, Poster Board #036 Poster Presentation Friday, Nov 9, 2012 8:30 - 10:30 am GMT SGI-110, a novel second generation DNA hypomethylating agent, enhances sorafenib activity and alters methylation signature of HCC cell lines Select posters will be made available for viewing on the company's website http://astx.com/pipeline/publications/ following the public presentation. About Astex Pharmaceuticals Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed DACOGEN(R) (decitabine) for Injection and receives significant royalties on global sales. For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com. The Astex Pharmaceuticals, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=12273 CONTACT: Timothy L. Enns Astex Pharmaceuticals, Inc. Senior Vice President Corporate Communications & Marketing Tel: +1 (925) 560-2810 E-mail: tim.enns@astx.com Alan Roemer The Trout Group Managing Director Tel: +1 (646) 378-2945 E-mail: aroemer@troutgroup.com Susanna Chau Astex Pharmaceuticals, Inc. Manager Investor Relations Tel: +1 (925) 560-2845 E-mail: susanna.chau@astx.com Kari Watson MacDougall Biomedical Communications Senior Vice President Tel: +1 (781) 235-3060 E-mail: kwatson@macbiocom.com News Source: NASDAQ OMX 31.10.2012 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Astex Pharmaceuticals, Inc. United States Phone: Fax: E-mail: Internet: ISIN: US04624B1035 WKN: End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found